Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2021-01-06 Board/Management Inform…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Appoints Sung Lee as Chief Financial Officer
Board/Management Information Classification · 1% confidence The document is a press release dated January 6, 2021, announcing the appointment of Sung Lee as the new Chief Financial Officer (CFO) of MorphoSys AG, effective February 2, 2021. This announcement details changes in senior management personnel. According to the definitions, announcements of changes in the company's board of directors or senior management fall under the 'Board/Management Information' category. Keywords supporting this: 'MorphoSys Appoints Sung Lee as Chief Financial Officer', 'succeeds Jens Holstein', 'member of the Management Board'. This clearly matches the definition for Board/Management Information (MANG) and is not an earnings release (ER), a full annual report (10-K), or a proxy statement (DEF 14A/PSI).
2021-01-06 English
MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
Regulatory Filings Classification · 1% confidence The document is a press release dated January 5, 2021, announcing that Swissmedic has accepted the Marketing Authorization Application (MAA) for the drug tafasitamab. It details the scope of the application (combination therapy for DLBCL), mentions ongoing clinical trials (L-MIND, RE-MIND), and discusses regulatory processes (Project Orbis with the FDA). This type of announcement, which communicates a specific regulatory milestone (MAA acceptance) and provides context on the drug's development and commercialization rights, is characteristic of a general corporate or regulatory update. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a transcript (CT), and it is a formal announcement of a regulatory step, it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory news item that doesn't fit the other specialized codes like ER, DIV, or CAP. Given the length and content, it is not merely an announcement of a report publication (RPA).
2021-01-05 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' regarding BlackRock, Inc.'s change in voting rights percentage (crossing thresholds) in MorphoSys AG, referencing the German Securities Trading Act (WpHG). This content directly corresponds to the definition of a notification of changes in significant share ownership levels, which matches the 'Major Shareholding Notification' category (MRQ). It is not a general earnings release (ER), a full annual report (10-K), or a proxy statement (PSI).
2020-12-28 English
MorphoSys AG: Corporate Calendar 2021
Report Publication Announcement Classification · 1% confidence The document is titled "MorphoSys AG: Corporate Calendar 2021" and explicitly lists future dates for key corporate events, including 'Publication of Interim Statement / Report', 'Conference Call', and 'Annual General Meeting'. This content is a forward-looking schedule of corporate events and reporting dates, not the actual financial report itself (like 10-K or IR) or an announcement of a specific report's publication (RPA). Since it details the schedule for the Annual General Meeting (AGM) and other key dates, it functions as general corporate/investor relations material related to upcoming meetings and reporting cycles. Given the options, this type of forward-looking calendar announcement, which includes the AGM date, is best classified as general Investor Relations material, but since there isn't a specific 'Corporate Calendar' code, I must choose the closest fit. It is not a specific filing type like 10-K, ER, or IR. It is an announcement about future events. The closest category that covers general investor-facing announcements that don't fit elsewhere, or materials related to the AGM schedule, is often grouped under general regulatory/investor news. However, since it specifically mentions the AGM date (May 19, 2021), and provides a calendar, it is highly relevant to AGM planning. Given the strict definitions, and noting that it is a calendar announcement, it is not a DEF 14A (Remuneration) or DVA (Voting Results). It is a schedule announcement. If we consider the AGM date listed, AGM-R (AGM Information) is plausible if this document were the presentation itself, but it is only the calendar. Since it is a general announcement detailing future reporting dates and the AGM date, and it is not a specific report, the most appropriate classification among the choices for a scheduled event announcement that isn't a specific report or a proxy statement is often RNS (Regulatory Filings/Miscellaneous Announcement) or potentially a very broad interpretation of AGM-R if the focus is heavily on the AGM date. Given the comprehensive nature of the calendar including quarterly reports, it leans towards general corporate news dissemination. I will select RNS as the best fit for a general corporate calendar announcement that doesn't match the specific report types, adhering to the principle that specific reports are not classified if only the schedule is provided.
2020-12-17 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in voting rights percentages held by a major shareholder (BlackRock, Inc.) in MorphoSys AG, referencing specific German securities law articles (WpHG, Sec. 33, 34, 38). This content directly corresponds to notifications regarding changes in significant share ownership thresholds, which aligns perfectly with the definition for Major Shareholding Notification (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the core content is the notification of a change in holding, not the results of a vote (DVA) or a general regulatory filing (RNS).
2020-12-10 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' regarding BlackRock, Inc.'s voting rights in MorphoSys AG, detailing the acquisition/disposal of shares and the resulting percentage change (from 5.40% to 5.24%). This content directly corresponds to the definition of a notification of changes in significant share ownership levels crossing thresholds, which aligns with the 'Major Shareholding Notification' category.
2020-12-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.